524606 — Beryl Drugs Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Beryl Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	128	141	146	269	267
Cost of Revenue
Gross Profit	62.1	66.7	62	123	136
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	126	139	153	258	257
Operating Profit	2.46	1.75	-6.78	11.3	10.8
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1.58	3.48	-9.5	9.84	10.1
Provision for Income Taxes
Net Income After Taxes	0.479	2.4	-6.59	7.66	7.69
Net Income Before Extraordinary Items
Net Income	0.479	2.4	-6.59	7.66	7.69
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	0.479	2.4	-6.59	7.66	7.69
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.095	0.472	-1.3	1.51	1.5